NCT02466373View on ClinicalTrials.gov

Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 5, 2018

Study Completion Date

April 5, 2018

Conditions
DeliriumCritical Illness
Interventions
DRUG

Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml

clonidine intravenous

Trial Locations (1)

Unknown

Deventer Hospital, Deventer

All Listed Sponsors
lead

Deventer Ziekenhuis

OTHER

NCT02466373 - Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients | Biotech Hunter | Biotech Hunter